Ozekibart added to chemotherapy demonstrates robust activity in relapsed/refractory Ewing sarcoma
Preliminary data on the tetravalent DR5 agonist indicate strong and durable responses with a manageable safety profile
The challenge of undifferentiated sarcomas
Recent studies have improved current understanding of clinical variability and molecular diversity of this subgroup, but many questions remain
Tailored combinations of tools are the way forward to assess quality of life in rare cancers
Recent studies emphasise that the current approach does not fully capture the needs and experiences of patients with rare tumours
New immunotherapy option emerges for low-risk gestational trophoblastic neoplasia
Adding first-line checkpoint inhibition to standard treatment shows promise to improve response in women
Why clinical practice guidelines matter even more in rare cancers
A recent EURACAN survey highlights a high uptake of recommendations from medical oncologists, potentially leading to improved patients’ survival
Ruiz: “Taking difficult decisions may change your career path for the better”
Becoming a gastrointestinal oncologist was unplanned, but Prof. Erika Ruiz is today glad of having built a rewarding career
How to close the age gap in clinical cancer research?
From geriatric assessment to artificial intelligence, an ESMO/SIOG paper highlights effective strategies to improve the representation of older patients in clinical trials
Research unlocks insights into lung cancer evolution from electronic medical records
A domain-specific natural language processing (NPL) pipeline showed strong performance in extracting clinically meaningful information from diverse clinical documents of patients with non-small cell lung cancer
Trustworthy and explainable AI – a key to equitable oncology?
Mitigating research biases by rigorous data analysis and validation can pave the way for a wider adoption of artificial intelligence in cancer care
RAS inhibition: a game changer in pancreatic cancer?
Preclinical findings show antitumour activity of triple KRAS inhibition in mouse models, but it will take years of rigorous research to assess its clinical efficacy in oncology patients